Mavrilimumab versus Anti tumor Necrosis Factor in Rheumatoid Arthritis

• Research type

  Research Study

• Full title

  A Phase 2 Exploratory Study of Mavrilimumab versus Anti tumor Necrosis Factor in Subjects with Rheumatoid Arthritis Protocol:CD-IA-CAM-3001-1107

• IRAS ID

  123448

• Contact name

  Andrew James Knowles Ostor

• Contact email

  andrew.ostor@addenbrookes.nhs.uk

• Sponsor organisation

  MedImmune Limited

• Eudract number

  2011-005649-10

• ISRCTN Number

  n/a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  13/EE/0144

• Date of REC Opinion

  5 Jul 2013

• REC opinion

  Further Information Favourable Opinion